Rhumbline Advisers T Scan Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 46,867 shares of TCRX stock, worth $266,673. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,867Holding current value
$266,673% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
85Shares Held
36.4MCall Options Held
0Put Options Held
0-
Eco R1 Capital, LLC San Francisco, CA5MShares$28.5 Million1.03% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$25.4 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$25 Million0.05% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$17 Million0.53% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$15.8 Million0.22% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $108M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...